brimonidine
AssetAlso called OCU300, AGN-190342 FREE BASE, NSC-318825, UK-14304
Brimonidine activates alpha-2 adrenergic receptors.
- Stage
- Phase 2, no development reported
- Modality
- Small molecule
- Target
- ADRA2A
- 1
- Indication
- 6
- Trials
- 1
- Developer
No development reported since March 2018. Last activity: Trial NCT03418727 completed. clinicaltrials.gov
Indications
1Dry eye syndrome
Phase 2, Completed, NCT03418727, clinicaltrials.gov, Nov 12, 2026
In the full profile
- Target and mechanism3
- Owner and partners1
- Trials6
- Evidence for its targets4
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.